Skip to main content
. 2021 Oct 7;9(10):1143. doi: 10.3390/vaccines9101143

Table 3.

Estimated vaccine effectiveness values for documented infection and symptomatic disease.

Period Documented Infection Symptomatic Disease
14–34 days after the first dose 97.7% (95.4–99.0%) 99.2% (96.4–99.8%)
14–41 days after the second dose 94.8% (87.0–97.8%) 97.2% (90.3–99.2%)
42–69 days after the second dose 83.0% (65.0–92.0%) 85.0% (63.0–94.2%)
>69 days after the second dose 81.0% (42.0–94.0%) 88.0% (42.0–97.6%)